ISPOR EU 2026

 

Healthcare decision-makers face increasing pressure to demonstrate value, accelerate access and generate evidence that reflects real-world patient experiences. ISPOR Europe 2026 brings together stakeholders across the healthcare ecosystem to advance discussions around health economics and outcomes research (HEOR), real-world evidence and patient-centered collaboration. 

At Syneos Health, we combine deep expertise in HEOR, value and access, market access strategy and real-world late phase research to help sponsors generate the evidence needed by patients, payers, providers and regulators. Our integrated teams transform real-world insights into actionable strategies that support commercialization, reimbursement and long-term product success across global markets. 

Meet with Us

Find us at booth #200

Meet with us at Booth #200 to explore how Syneos Health transforms real-world insights into evidence strategies that support value demonstration, market access and long-term commercial success. Our experts in HEOR, value & access and real-world evidence can help you navigate increasingly complex healthcare decision-making environments. 

---

Poster Sessions:

Leveraging Joint Clinical Assessment to Harmonize HTA Decisions Across Europe

As Europe's Joint Clinical Assessment framework takes shape, organizations are navigating how to align evidence strategies across multiple markets. This poster explores opportunities to improve consistency in health technology assessment decision-making while supporting efficient evidence generation. Discover how emerging EU assessment requirements may shape evidence planning and market access strategies across Europe.

• The evolving role of Joint Clinical Assessment in European HTA processes
• Explore methodological and policy challenges that may limit the impact of the JCA
• Identify practical ways to strengthen JCA role in equitable patient access

The Global Ripple Effect of US Drug Pricing Reforms: Manufacturer Strategies, Payer Counter-Offensives, and HEOR Transformation Ex-US

Policy changes in one market can have far-reaching implications elsewhere. This poster examines how US drug pricing reforms may influence manufacturer decision-making, payer responses, and evidence-generation priorities across global markets. See how stakeholders are responding to a shifting policy landscape and what it could mean for access and value demonstration outside the US.

• Potential downstream effects of US drug pricing reforms on international markets
• Emerging manufacturer and payer responses to policy change
• Implications for HEOR, evidence generation, and market access planning

The Invisible Burden of Glioblastoma: Combining Literature Review with Patient and Caregiver Qualitative Insights

Glioblastoma affects patients and caregivers in many ways, and while direct medical costs are well characterised, indirect costs and broader societal impacts remain underrepresented. This poster combines published evidence with insights from a patient and caregiver survey to provide a broader view of the disease burden. Gaining a deeper understanding of the lived experiences can support the development of more robust, patient-centered value propositions that reflect the true societal and economic impact of glioblastoma.

• The economic and financial impact of glioblastoma on patients and caregivers
• Patient and caregiver insights from qualitative and quantitative survey research, contextualized by published evidence
• Opportunities to strengthen patient-centered research and care approaches

Assessing Evidence Transferability Between EU Joint Clinical Assessment and National HTA in Rare Oncology: A Cross-Market Framework

Rare oncology presents distinct challenges for evidence generation and assessment across Europe, where differences in comparators, evidence expectations, and therapeutic positioning limit the transferability of a common evidence package. This poster explores a structured cross-market framework to assess how evidence developed for EU Joint Clinical Assessment (JCA) may translate to national HTA requirements and where additional evidence needs may remain. Explore the poster to learn about:

• Evidence transferability between EU JCA and national HTA environments
• Key areas of alignment and divergence across evidence requirements
• Evidence gaps and country-specific adaptation needs across rare-oncology therapy archetypes

Toward AI-Augmented Screening for HTA-Relevant Evidence Synthesis: Validation of a Governed Single-Reviewer Workflow

The growing complexity of HTA submissions and expanding evidence requirements have increased the need for more efficient evidence-generation approaches without compromising scientific rigor. This poster evaluates an AI-supported screening approach within a governed workflow. Discover how technology and expert oversight can work together to support more efficient evidence synthesis.

• The role of AI in literature screening and evidence review
• Validation of a governed single-reviewer workflow against human reviewer decisions
• Opportunities to improve efficiency while maintaining quality standards in evidence generation

Assessing the Incremental Value of Patient Experience Evidence in HTA and Reimbursement Decision-Making

Patient experience evidence (PEE) is increasingly relevant to healthcare value assessment, yet its contribution to health technology assessment (HTA) and reimbursement decision-making remains inconsistent. This poster explores how PEE can add incremental value alongside conventional clinical and economic evidence.

• How PEE can add incremental value to HTA and reimbursement decision-making
• Methodological considerations influencing the decision relevance of PEE
• Opportunities to integrate PEE across value dossiers, economic models, and HTA strategies

Integrating Discrete Choice Experiment Evidence into Health Economic Evaluations: A Framework for Patient-Centered Value Assessment

Patient preferences play an important role in understanding healthcare value. This poster presents a framework for incorporating discrete choice experiment evidence into health economic evaluations. Explore how preference data can be used to support more patient-centered assessment approaches.

• Approaches to integrating patient preference evidence into economic evaluation
• The role of discrete choice experiments in value assessment
• Methods for supporting more patient-centered decision-making

Our Capabilities:

Real World Evidence Late Phase

HEOR

Consulting Value and Access

Market Access and Patient Support

Insights and Evidence Generation

Insights:

White Paper I From Static FSP to Operating Models That Keep Pace With Change

White Paper I Mitigating Manufacturer Exposure to US MFN Policy

White Paper I Understanding the EU Joint Clinical Assessment (JCA) Implementation

Related Content:

Want to learn more? Explore Insights Hub for our latest perspectives,  subscribe to our podcast.